Pharmacogenetics of irinotecan and oxaliplatin in advanced colorectal cancer Kweekel, D.M.

Pharmacogenetics of irinotecan and oxaliplatin in advanced colorectal cancer

Kweekel, D.M.

Citation

Kweekel, D. M. (2009, May 26). Pharmacogenetics of irinotecan and oxaliplatin in advanced colorectal cancer. Retrieved from https://hdl.handle.net/1887/13820

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded from: https://hdl.handle.net/1887/13820

Note: To cite this publication please use the final published version (if applicable).

Pharmacogenetics of irinotecan and oxaliplatin in advanced colorectal cancer

© 2009, D.M. Kweekel, The Netherlands

ISBN: 978-90-9024108-1

Designed byMEGLA;MAINLY DESIGN Printed by Optima Grafische Communicatie

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission of the copyright owner.

The research presented in this thesis was performed at the Department of Clinical Pharmacy and Toxicology of the Leiden University Medical Center, The Netherlands. Publication of this thesis was sponsored by the AZL Onderzoeks- en Ontwikkelings-krediet (OOK) Apotheek and the Stichting Klinische Oncologie Leiden (SKOL).

PHARMACOGENETICS OF IRINOTECAN AND OXALIPLATIN

IN ADVANCED COLORECTAL CANCER

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,

volgens besluit van het College voor Promoties te verdedigen op dinsdag 26 mei 2009

klokke 15:00uur

door

DINA MARIA KWEEKEL

geboren te Leiderdorp

in 1975

PROMOTIECOMMISSIE

Promotores:

Prof. Dr. H.-J. Guchelaar Prof. Dr. J.W.R. Nortier

Prof. Dr. C.J.A. Punt Universiteit Nijmegen

Co-promotor:

Dr. A.J. Gelderblom

Overige leden:

Prof. Dr. J. Morreau Prof. Dr. G.J.B. van Ommen Prof. Dr. R.A.E.M. Tollenaar

Prof. Dr. A.C.G. Egberts Universiteit Utrecht Prof. Dr. D.J. Richel Universiteit van Amsterdam Prof. Dr. J.H.M. Schellens Universiteit Utrecht

CONTENTS

1

Introduction 7

PART I: GENERAL PHARMACOGENETICS

2

Multiplex pyrosequencing of two polymorphisms

in DNA repair gene XRCC1 J Mol Diagn. 2006 Sep;8(4):444-8 21

3

Comparison of genetic polymorphisms in DNA isolated

from blood and paraffin embedded colorectal cancer tissue Submitted 33

PART II: FOCUS ON IRINOTECAN

4

Clinical and pharmacogenetic factors associated

with irinotecan toxicity Cancer Treat Rev. 2008 Nov;34(7):656-69 45

5

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: A Dutch Colorectal Cancer

Group study Br J Cancer. 2008 Jul 22;99(2):275-82 73

6

GSTP1 Ile105Val polymorphism correlates with progression free survival in MCRC patients treated with or without irinotecan:

A study of the Dutch Colorectal Cancer Group

Br J Cancer. 2008 Oct 21;99(8):1316-21 93

PART III: FOCUS ON OXALIPLATIN

7

Pharmacology of oxaliplatin and the use of pharmacogenomics

to individualize therapy Cancer Treat Rev. 2005 Apr;31(2):90-105 107

8

Clinical and functional studies on ERCC1 polymorphisms

and protein function in colorectal cancer patients treated with oxaliplatin 135

9

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced

colorectal cancer patients Eur J Cancer 2009 Mar, 45: 572-578 155

10

Explorative study to identify novel candidate genes related to

oxaliplatin efficacy and toxicity using a DNA repair array Submitted 169

11

General Discussion & Conclusion 183

Summary 197

Nederlandse Samenvatting 200

Dankwoord 205

List of Publications 206

Curriculum Vitae 207